Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002008 · ClinicalTrials.gov registry record · Phase 1
An Open Label Phase I Study of Subcutaneously Administered Recombinant Human GM-CSF in Patients With AIDS Virus Infection and Leukopenia
A Phase 1 study, sponsored by Sandoz.
- Completed
- Registry status
- Phase 1
- Development phase
NCT00002008: Completed Phase 1 study, sponsored by Sandoz.
NCT00002008 is a Phase 1 study that has completed, run by Sandoz. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00002008, a Phase 1 study, has completed, sponsored by Sandoz.
- COMPLETED
- Registry status
- Phase 1
- Development phase
Study Summary
To determine the safety, immunogenicity, biological activity, ad pharmacokinetics of sargramostim ( recombinant granulocyte-macrophage colony-stimulating factor; GM-CSF ) human granulocyte-macrophage colony-stimulating factor ( GM-CSF ), given by subcutaneous ( SC ) injection to patients with leukopenia in association with HIV infection.
Interventions
- DRUG Sargramostim
Trial Details
| Field | Value |
|---|---|
| Phase | Phase 1 |
What the finished NCT00002008 record still lists
NCT00002008 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 1 intervention - of which Sargramostim is the first listed.
NCT00002008 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00002008 about?
NCT00002008 is a clinical study titled "An Open Label Phase I Study of Subcutaneously Administered Recombinant Human GM-CSF in Patients With AIDS Virus Infection and Leukopenia". To determine the safety, immunogenicity, biological activity, ad pharmacokinetics of sargramostim ( recombinant granulocyte-macrophage colony-stimulating factor; GM-CSF ) human granulocyte-macrophage colony-stimulating factor ( GM-CSF ), given by subcutaneous ( SC ) injection to patients with leukop...
What is the current status of trial NCT00002008?
This trial is currently completed. It is a Phase 1 study.
What interventions are being tested in trial NCT00002008?
The interventions under investigation include: Sargramostim (DRUG).
Who is sponsoring clinical trial NCT00002008?
This trial is sponsored by Sandoz, which has 29 total clinical trials registered on ClinicalTrials.gov.